ArticleThoracic cancer2022

First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations.

Noriaki Ito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.